<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02204579</url>
  </required_header>
  <id_info>
    <org_study_id>CAL-C13-001</org_study_id>
    <nct_id>NCT02204579</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations</brief_title>
  <official_title>Open-label Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous NPSP795 in Autosomal Dominant Hypocalcemia Due to Mutations in the Calcium-sensing Receptor Gene: A Drug Repurposing Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study looking at the effects of NPSP795 (a selective calcium receptor
      antagonist) on activating mutations of the Calcium-sensing receptor in patients with
      Autosomal Dominant Hypocalcemia. Patients with ADH have low blood calcium levels and an
      inappropriately increased renal calcium excretion, decreased renal phosphate excretion, and
      hyperphosphatemia. PTH and blood calcium levels will be tested during and after the IV
      infusion of NPSP795. Concentrations of NPSP795 and length of time of IV infusion will vary
      depending on measured levels of ionized calcium.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)</measure>
    <time_frame>From Day 1 up to safety follow-up assessment (upto Day 17 after discharge)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Vital Signs and Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>From Day 1 up to safety follow-up assessment (upto Day 17 after discharge)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Potentially Clinically Important Laboratory Abnormalities</measure>
    <time_frame>From Day 1 up to safety follow-up assessment (upto Day 17 after discharge)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormalities Related to Physical Examination</measure>
    <time_frame>From Day 1 up to safety follow-up assessment (upto Day 17 after discharge)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Ionised Calcium at Specified Timepoint</measure>
    <time_frame>Baseline (Predose), 4 Hours and 8 Hours Postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Serum Calcium at 12 Hours Postdose</measure>
    <time_frame>Baseline (Predose) to 12 Hours Postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Urinary Calcium at 12 Hours Postdose</measure>
    <time_frame>Baseline (Predose) to 12 Hours Postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Serum Parathyroid Hormone (PTH) at Specified Time Point</measure>
    <time_frame>Baseline (Predose), 5.5 Hours, 8 Hours Postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC[0-t]) of NPSP795</measure>
    <time_frame>Baseline (Predose), and 15, 30 Minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 5.5 and 8 Hours Postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve Extrapolated to Infinity (AUC0-infinity) of NPSP795</measure>
    <time_frame>Baseline (Predose), and 15, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 5.5 and 8 Hours Postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Drug Concentration (Cmax) of NPSP795 in Plasma</measure>
    <time_frame>Baseline (Predose), and 15, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 5.5 and 8 Hours Postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-life (t1/2) of NPSP795 in Plasma</measure>
    <time_frame>Baseline (Predose), and 15, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 5.5 and 8 Hours Postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fractional Excretion of Calcium (FECa) at 12 Hours Postdose</measure>
    <time_frame>Baseline (Predose) to 12 Hours Postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Autosomal Dominant Hypocalcemia (ADH)</condition>
  <arm_group>
    <arm_group_label>NPSP795</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPSP795</intervention_name>
    <arm_group_label>NPSP795</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a heterozygous activating mutation of the CaSR gene (ADH); if not
             previously confirmed, genetic testing will be performed at the screening visit

          -  At least 18 years of age

          -  Body mass index (BMI) ≥ 18.5 to &lt; 39 kg/m2

        Exclusion Criteria:

          -  Diseases or conditions that might compromise any major body system or interfere with
             the pharmacokinetics of NPSP795

          -  History of treatment with PTH 1-84 or 1-34 within the previous 6 months

          -  History of hypocalcemia requiring frequent IV calcium infusions

          -  History of hypocalcemic seizure within the past 3 months

          -  Blood 25-hydroxy vitamin D level &lt; 25 ng/mL. If subjects have a blood 25-hydroxy
             vitamin D level &lt; 25 ng/mL at the outpatient screening visit, they will be prescribed
             vitamin D replacement. Once the 25-hydroxy vitamin D level is &gt; 25 ng/mL, the subject
             will be eligible to continue on to the treatment phase of the study

          -  Estimated glomerular filtration rate (GFR) &lt; 25 mL/minute, and/or abnormal hepatic,
             hematologic, and/or clotting function

          -  12 lead resting electrocardiogram (ECG) with clinically significant abnormalities

          -  Concomitant medications with the potential to interfere with NPSP795 metabolism

          -  History of thyroid or parathyroid surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institute of Health (NIH)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2014</study_first_submitted>
  <study_first_submitted_qc>July 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2014</study_first_posted>
  <results_first_submitted>October 27, 2016</results_first_submitted>
  <results_first_submitted_qc>October 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 21, 2016</results_first_posted>
  <disposition_first_submitted>March 7, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>June 17, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 21, 2016</disposition_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autosomal Dominant Hypocalcemia</keyword>
  <keyword>Hypocalcemia</keyword>
  <keyword>ADH</keyword>
  <keyword>Hypoparathyroidism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypocalcemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NPSP795</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Started in Pre-Amendment</title>
              <participants_list>
                <participants group_id="P1" count="2">Two participants completed treatment in pre-amendment and were re-enrolled in post-amendment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Started in Post-Amendment</title>
              <participants_list>
                <participants group_id="P1" count="5">Two participants from pre-amendment were re-enrolled with different identification numbers.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen failures</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NPSP795</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.8" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)</title>
        <time_frame>From Day 1 up to safety follow-up assessment (upto Day 17 after discharge)</time_frame>
        <population>Safety population included all participants who received at least 1 minute of study drug infusion (pre-amendment and post-amendment).</population>
        <group_list>
          <group group_id="O1">
            <title>NPSP795</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)</title>
          <population>Safety population included all participants who received at least 1 minute of study drug infusion (pre-amendment and post-amendment).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with TESAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Vital Signs and Electrocardiogram (ECG) Abnormalities</title>
        <time_frame>From Day 1 up to safety follow-up assessment (upto Day 17 after discharge)</time_frame>
        <population>Safety population included all participants who received at least 1 minute of study drug infusion (both pre-amendment and post-amendment participants).</population>
        <group_list>
          <group group_id="O1">
            <title>NPSP795</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Vital Signs and Electrocardiogram (ECG) Abnormalities</title>
          <population>Safety population included all participants who received at least 1 minute of study drug infusion (both pre-amendment and post-amendment participants).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Potentially Clinically Important Laboratory Abnormalities</title>
        <time_frame>From Day 1 up to safety follow-up assessment (upto Day 17 after discharge)</time_frame>
        <population>Safety population included all participants who received at least 1 minute of study drug infusion (pre-amendment and post-amendment).</population>
        <group_list>
          <group group_id="O1">
            <title>NPSP795</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potentially Clinically Important Laboratory Abnormalities</title>
          <population>Safety population included all participants who received at least 1 minute of study drug infusion (pre-amendment and post-amendment).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Abnormalities Related to Physical Examination</title>
        <time_frame>From Day 1 up to safety follow-up assessment (upto Day 17 after discharge)</time_frame>
        <population>Safety population included all participants who received at least 1 minute of study drug infusion (both pre-amendment and post-amendment participants).</population>
        <group_list>
          <group group_id="O1">
            <title>NPSP795</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Abnormalities Related to Physical Examination</title>
          <population>Safety population included all participants who received at least 1 minute of study drug infusion (both pre-amendment and post-amendment participants).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Ionised Calcium at Specified Timepoint</title>
        <time_frame>Baseline (Predose), 4 Hours and 8 Hours Postdose</time_frame>
        <population>Post-amendment pharmacodynamic (PD) analysis population included all participants who received at least 5 minutes of the study drug infusion and had at least one PD measurement on at least 1 day of infusion. Here, n=number of participants analysed for specified category at the specified time points in each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>NPSP795 on Day 1 (5 mg/10 Minutes)</title>
          </group>
          <group group_id="O2">
            <title>NPSP795 on Day 2 (15 mg/3.5 Hours)</title>
          </group>
          <group group_id="O3">
            <title>NPSP795 on Day 3 (30 mg/3.5 Hours)</title>
          </group>
          <group group_id="O4">
            <title>NPSP795 on Day 4 (30 mg/3.5 Hours)</title>
          </group>
          <group group_id="O5">
            <title>NPSP795 on Day 4 (50 mg/3.5 Hours)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Ionised Calcium at Specified Timepoint</title>
          <population>Post-amendment pharmacodynamic (PD) analysis population included all participants who received at least 5 minutes of the study drug infusion and had at least one PD measurement on at least 1 day of infusion. Here, n=number of participants analysed for specified category at the specified time points in each arm respectively.</population>
          <units>millimole/liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=5,5,5,3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.972" spread="0.058"/>
                    <measurement group_id="O2" value="0.950" spread="0.054"/>
                    <measurement group_id="O3" value="0.986" spread="0.045"/>
                    <measurement group_id="O4" value="0.933" spread="0.055"/>
                    <measurement group_id="O5" value="1.025" spread="0.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 4 Hours Post dose (n=5,5,5,3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.016" spread="0.027"/>
                    <measurement group_id="O2" value="0.010" spread="0.026"/>
                    <measurement group_id="O3" value="-0.014" spread="0.023"/>
                    <measurement group_id="O4" value="-0.030" spread="0.046"/>
                    <measurement group_id="O5" value="-0.015" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 8 Hours Post dose (n=5,5,5,3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data was calculated for 5 mg/10 minutes infusion until hour 4 only.</measurement>
                    <measurement group_id="O2" value="-0.034" spread="0.044"/>
                    <measurement group_id="O3" value="-0.040" spread="0.060"/>
                    <measurement group_id="O4" value="-0.033" spread="0.046"/>
                    <measurement group_id="O5" value="-0.060" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Serum Calcium at 12 Hours Postdose</title>
        <time_frame>Baseline (Predose) to 12 Hours Postdose</time_frame>
        <population>Post-amendment PD analysis population included all participants who received at least 5 minutes of the study drug infusion and had at least one PD measurement on at least 1 day of infusion. Here, n=number of participants analysed for specified category at the specified time points in each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>NPSP795 on Day 1 (5 mg/10 Minutes)</title>
          </group>
          <group group_id="O2">
            <title>NPSP795 on Day 2 (15 mg/3.5 Hours)</title>
          </group>
          <group group_id="O3">
            <title>NPSP795 on Day 3 (30 mg/3.5 Hours)</title>
          </group>
          <group group_id="O4">
            <title>NPSP795 on Day 4 (30 mg/3.5 Hours)</title>
          </group>
          <group group_id="O5">
            <title>NPSP795 on Day 4 (50 mg/3.5 Hours)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Calcium at 12 Hours Postdose</title>
          <population>Post-amendment PD analysis population included all participants who received at least 5 minutes of the study drug infusion and had at least one PD measurement on at least 1 day of infusion. Here, n=number of participants analysed for specified category at the specified time points in each arm respectively.</population>
          <units>millimole/liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=5,5,5,3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.914" spread="0.157"/>
                    <measurement group_id="O2" value="1.790" spread="0.125"/>
                    <measurement group_id="O3" value="1.852" spread="0.132"/>
                    <measurement group_id="O4" value="1.677" spread="0.135"/>
                    <measurement group_id="O5" value="1.980" spread="0.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 12 Hours Postdose (n=5,5,5,3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.114" spread="0.141"/>
                    <measurement group_id="O2" value="-0.042" spread="0.054"/>
                    <measurement group_id="O3" value="-0.106" spread="0.079"/>
                    <measurement group_id="O4" value="-0.040" spread="0.053"/>
                    <measurement group_id="O5" value="-0.270" spread="0.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Urinary Calcium at 12 Hours Postdose</title>
        <time_frame>Baseline (Predose) to 12 Hours Postdose</time_frame>
        <population>PD analysis population included all participants who received at least 5 minutes of the study drug infusion and had at least one PD measurement on at least 1 day of infusion. Here, n=number of participants analysed for specified category at the specified time points in each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>NPSP795 on Day 1 (5 mg/10 Minutes)</title>
          </group>
          <group group_id="O2">
            <title>NPSP795 on Day 2 (15 mg/3.5 Hours)</title>
          </group>
          <group group_id="O3">
            <title>NPSP795 on Day 3 (30 mg/3.5 Hours)</title>
          </group>
          <group group_id="O4">
            <title>NPSP795 on Day 4 (30 mg/3.5 Hours)</title>
          </group>
          <group group_id="O5">
            <title>NPSP795 on Day 4 (50 mg/3.5 Hours)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urinary Calcium at 12 Hours Postdose</title>
          <population>PD analysis population included all participants who received at least 5 minutes of the study drug infusion and had at least one PD measurement on at least 1 day of infusion. Here, n=number of participants analysed for specified category at the specified time points in each arm respectively.</population>
          <units>millimole/liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=5,5,5,3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.302" spread="2.283"/>
                    <measurement group_id="O2" value="3.912" spread="3.299"/>
                    <measurement group_id="O3" value="2.936" spread="1.750"/>
                    <measurement group_id="O4" value="2.537" spread="1.968"/>
                    <measurement group_id="O5" value="2.065" spread="1.916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 12 Hours Postdose (n=5,5,5,3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.590" spread="0.861"/>
                    <measurement group_id="O2" value="-2.162" spread="2.027"/>
                    <measurement group_id="O3" value="-1.188" spread="1.634"/>
                    <measurement group_id="O4" value="-1.190" spread="1.460"/>
                    <measurement group_id="O5" value="-0.755" spread="1.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Serum Parathyroid Hormone (PTH) at Specified Time Point</title>
        <time_frame>Baseline (Predose), 5.5 Hours, 8 Hours Postdose</time_frame>
        <population>Post amendment PD analysis population included all participants who received at least 5 minutes of the study drug infusion and had at least one PD measurement on at least 1 day of infusion. Here, n=number of participants analysed for specified category at the specified time points in each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>NPSP795 on Day 1 (5 mg/10 Minutes)</title>
          </group>
          <group group_id="O2">
            <title>NPSP795 on Day 2 (15 mg/3.5 Hours)</title>
          </group>
          <group group_id="O3">
            <title>NPSP795 on Day 3 (30 mg/3.5 Hours)</title>
          </group>
          <group group_id="O4">
            <title>NPSP795 on Day 4 (30 mg/3.5 Hours)</title>
          </group>
          <group group_id="O5">
            <title>NPSP795 on Day 4 (50 mg/3.5 Hours)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Parathyroid Hormone (PTH) at Specified Time Point</title>
          <population>Post amendment PD analysis population included all participants who received at least 5 minutes of the study drug infusion and had at least one PD measurement on at least 1 day of infusion. Here, n=number of participants analysed for specified category at the specified time points in each arm respectively.</population>
          <units>nanogram/liter (ng/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=5,5,5,3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.32" spread="2.93"/>
                    <measurement group_id="O2" value="9.14" spread="3.29"/>
                    <measurement group_id="O3" value="9.58" spread="5.32"/>
                    <measurement group_id="O4" value="12.80" spread="8.68"/>
                    <measurement group_id="O5" value="7.40" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 5.5 Hours Postdose (n=5,5,5,3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data for 10 minutes infusion was not calculated at 5.5-hours.</measurement>
                    <measurement group_id="O2" value="0.84" spread="0.86"/>
                    <measurement group_id="O3" value="1.92" spread="1.53"/>
                    <measurement group_id="O4" value="0.13" spread="1.50"/>
                    <measurement group_id="O5" value="1.75" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 8 Hours Postdose (n=5,5,5,3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="1.56"/>
                    <measurement group_id="O2" value="NA">Data for 3.5-hours infusions was calculated until hour 5.5 only.</measurement>
                    <measurement group_id="O3" value="NA">Data for 3.5-hours infusions was calculated until hour 5.5 only.</measurement>
                    <measurement group_id="O4" value="NA">Data for 3.5-hours infusions was calculated until hour 5.5 only.</measurement>
                    <measurement group_id="O5" value="NA">Data for 3.5-hours infusions was calculated until hour 5.5 only.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC[0-t]) of NPSP795</title>
        <time_frame>Baseline (Predose), and 15, 30 Minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 5.5 and 8 Hours Postdose</time_frame>
        <population>Post amendment pharmacokinetic (PK) analysis population included all participants who received at least 5 minutes of the study drug infusion and had at least one PK measurement on at least 1 day of infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>NPSP795 on Day 1 (5 mg/10 Minutes)</title>
          </group>
          <group group_id="O2">
            <title>NPSP795 on Day 2 (15 mg/3.5 Hours)</title>
          </group>
          <group group_id="O3">
            <title>NPSP795 on Day 3 (30 mg/3.5 Hours)</title>
          </group>
          <group group_id="O4">
            <title>NPSP795 on Day 4 (30 mg/3.5 Hours)</title>
          </group>
          <group group_id="O5">
            <title>NPSP795 on Day 4 (50 mg/3.5 Hours)</title>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC[0-t]) of NPSP795</title>
          <population>Post amendment pharmacokinetic (PK) analysis population included all participants who received at least 5 minutes of the study drug infusion and had at least one PK measurement on at least 1 day of infusion.</population>
          <units>nanogram*hour per millilitre (ng·h/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309.512" spread="122.601"/>
                    <measurement group_id="O2" value="795.766" spread="294.345"/>
                    <measurement group_id="O3" value="1561.746" spread="546.479"/>
                    <measurement group_id="O4" value="1657.057" spread="650.156"/>
                    <measurement group_id="O5" value="2251.818" spread="568.782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Time Curve Extrapolated to Infinity (AUC0-infinity) of NPSP795</title>
        <time_frame>Baseline (Predose), and 15, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 5.5 and 8 Hours Postdose</time_frame>
        <population>Post amendment PK analysis population included all participants who received at least 5 minutes of the study drug infusion and had at least one PK measurement on at least 1 day of infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>NPSP795 on Day 1 (5 mg/10 Minutes)</title>
          </group>
          <group group_id="O2">
            <title>NPSP795 on Day 2 (15 mg/3.5 Hours)</title>
          </group>
          <group group_id="O3">
            <title>NPSP795 on Day 3 (30 mg/3.5 Hours)</title>
          </group>
          <group group_id="O4">
            <title>NPSP795 on Day 4 (30 mg/3.5 Hours)</title>
          </group>
          <group group_id="O5">
            <title>NPSP795 on Day 4 (50 mg/3.5 Hours)</title>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Curve Extrapolated to Infinity (AUC0-infinity) of NPSP795</title>
          <population>Post amendment PK analysis population included all participants who received at least 5 minutes of the study drug infusion and had at least one PK measurement on at least 1 day of infusion.</population>
          <units>nanogram*hour per milliliter(ng·h/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.672" spread="1.775"/>
                    <measurement group_id="O2" value="5.572" spread="2.724"/>
                    <measurement group_id="O3" value="5.437" spread="2.587"/>
                    <measurement group_id="O4" value="7.648" spread="3.607"/>
                    <measurement group_id="O5" value="4.521" spread="2.991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Drug Concentration (Cmax) of NPSP795 in Plasma</title>
        <time_frame>Baseline (Predose), and 15, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 5.5 and 8 Hours Postdose</time_frame>
        <population>Post amendment PK analysis population included all randomized participants who received at least 5 minutes of the study drug infusion and had at least one PK measurement on at least one day of infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>NPSP795 on Day 1 (5 mg/10 Minutes)</title>
          </group>
          <group group_id="O2">
            <title>NPSP795 on Day 2 (15 mg/3.5 Hours)</title>
          </group>
          <group group_id="O3">
            <title>NPSP795 on Day 3 (30 mg/3.5 Hours)</title>
          </group>
          <group group_id="O4">
            <title>NPSP795 on Day 4 (30 mg/3.5 Hours)</title>
          </group>
          <group group_id="O5">
            <title>NPSP795 on Day 4 (50 mg/3.5 Hours)</title>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Drug Concentration (Cmax) of NPSP795 in Plasma</title>
          <population>Post amendment PK analysis population included all randomized participants who received at least 5 minutes of the study drug infusion and had at least one PK measurement on at least one day of infusion.</population>
          <units>nanogram/milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301.900" spread="120.664"/>
                    <measurement group_id="O2" value="745.335" spread="254.205"/>
                    <measurement group_id="O3" value="1467.102" spread="475.343"/>
                    <measurement group_id="O4" value="1515.086" spread="548.056"/>
                    <measurement group_id="O5" value="2141.500" spread="475.706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Half-life (t1/2) of NPSP795 in Plasma</title>
        <time_frame>Baseline (Predose), and 15, 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 5.5 and 8 Hours Postdose</time_frame>
        <population>Post amendment PK analysis population included all participants who received at least 5 minutes of the study drug infusion and had at least one PK measurement on at least 1 day of infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>NPSP795 on Day 1 (5 mg/10 Minutes)</title>
          </group>
          <group group_id="O2">
            <title>NPSP795 on Day 2 (15 mg/3.5 Hours)</title>
          </group>
          <group group_id="O3">
            <title>NPSP795 on Day 3 (30 mg/3.5 Hours)</title>
          </group>
          <group group_id="O4">
            <title>NPSP795 on Day 4 (30 mg/3.5 Hours)</title>
          </group>
          <group group_id="O5">
            <title>NPSP795 on Day 4 (50 mg/3.5 Hours)</title>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half-life (t1/2) of NPSP795 in Plasma</title>
          <population>Post amendment PK analysis population included all participants who received at least 5 minutes of the study drug infusion and had at least one PK measurement on at least 1 day of infusion.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.013" spread="0.612"/>
                    <measurement group_id="O2" value="3.913" spread="0.222"/>
                    <measurement group_id="O3" value="4.213" spread="0.449"/>
                    <measurement group_id="O4" value="3.839" spread="0.294"/>
                    <measurement group_id="O5" value="4.000" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fractional Excretion of Calcium (FECa) at 12 Hours Postdose</title>
        <time_frame>Baseline (Predose) to 12 Hours Postdose</time_frame>
        <population>Post-amendment PD analysis population included all participants who received at least 5 minutes of the study drug infusion and had at least one PD measurement on at least 1 day of infusion. Here n=number of participants analysed for specified category at the specified time points in each arm respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>NPSP795 on Day 1 (5 mg/10 Minutes)</title>
          </group>
          <group group_id="O2">
            <title>NPSP795 on Day 2 (15 mg/3.5 Hours)</title>
          </group>
          <group group_id="O3">
            <title>NPSP795 on Day 3 (30 mg/3.5 Hours)</title>
          </group>
          <group group_id="O4">
            <title>NPSP795 on Day 4 (30 mg/3.5 Hours)</title>
          </group>
          <group group_id="O5">
            <title>NPSP795 on Day 4 (50 mg/3.5 Hours)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fractional Excretion of Calcium (FECa) at 12 Hours Postdose</title>
          <population>Post-amendment PD analysis population included all participants who received at least 5 minutes of the study drug infusion and had at least one PD measurement on at least 1 day of infusion. Here n=number of participants analysed for specified category at the specified time points in each arm respectively.</population>
          <units>Fraction of excretion</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FECa: Baseline (n=5,5,5,3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.030" spread="0.023"/>
                    <measurement group_id="O2" value="0.031" spread="0.017"/>
                    <measurement group_id="O3" value="0.027" spread="0.014"/>
                    <measurement group_id="O4" value="0.030" spread="0.011"/>
                    <measurement group_id="O5" value="0.026" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FECa: Change at 12 Hours Postdose (n=5,5,5,3,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002" spread="0.005"/>
                    <measurement group_id="O2" value="0.002" spread="0.012"/>
                    <measurement group_id="O3" value="0.001" spread="0.011"/>
                    <measurement group_id="O4" value="-0.009" spread="0.018"/>
                    <measurement group_id="O5" value="0.002" spread="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the sign of informed consent form (Day -93) up to safety follow-up assessment (upto Day 17 after discharge)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NPSP795</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Nipple pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire</organization>
      <phone>1 866-842-5335</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

